| AMPA | Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid |
| BBB | Blood-brain barrier |
| EPSP | Excitatory postsynaptic potential |
| FDA | Food and Drug Administration |
| IND | Investigational new drug |
| ADHD | Attention-deficit hyperactivity disorder |
| TDS | Thiamine disulfide system |
| EDCI | 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride |
| HOBT | N-Hydroxybenzotriazole |
| DMAP | 4-Dimethylaminopyridine |
| TEA | Triethylamine |
| DCM | Dichloromethane |
| rt | Room temperature |
| MRT | Mean residence times |
| RD | Respiratory depression |
| sc | Subcutaneous injection |
| iv | Intravenous injection |
| NMR | Nuclear Magnetic Resonance |
| LC | Liquid chromatography |
| MS | Mass spectrometry |
| ESI | Electrospray ionization |
| CAD | Collision-activated dissociation |
| CE | Collision energies |
| USA | United States of America |
| TMS | Tetramethylsilane |